STOCK TITAN
  1. Home
  2. News
  3. BIAF

bioAffinity Technologies, Inc. - BIAF STOCK NEWS

Welcome to our dedicated page for bioAffinity Technologies news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Technologies stock.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) is a pioneering biotechnology company dedicated to addressing the critical need for the early detection and targeted treatment of cancer and lung diseases. The company develops proprietary, noninvasive diagnostic tests and cancer therapeutics that focus on the cellular level, which has the potential to significantly improve patient outcomes.

One of the company’s leading innovations is the CyPath® Lung test, a noninvasive diagnostic tool designed to detect early-stage lung cancer. This test employs flow cytometry technology to analyze sputum samples, which can dramatically increase diagnostic accuracy, reduce the need for invasive procedures, and lower medical costs while enhancing patient comfort and survival rates. CyPath® Lung has been licensed by Precision Pathology Services for further development and commercial sale as a laboratory-developed test.

Recent company milestones include a securities purchase agreement with institutional investors, announced on March 6, 2024, by WallachBeth Capital LLC. This agreement involves a registered direct offering and a concurrent private placement, expected to raise approximately $2.5 million. The proceeds will support the company's ongoing research, development activities, and potential commercialization efforts.

Financially, bioAffinity Technologies is actively engaging with institutional investors to secure funding necessary for its ambitious projects. The company’s efforts are supported by an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and the strategic guidance of WallachBeth Capital, which provides comprehensive capital market and investment banking services tailored to the healthcare sector.

Through its innovative approach and strong industry partnerships, bioAffinity Technologies aims to revolutionize cancer diagnosis and treatment, ultimately improving survival rates and quality of life for patients worldwide.

News

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has announced a securities purchase agreement with institutional investors for the sale of 1,600,000 shares of common stock and common warrants. The purchase price is $1.5625 per share, with warrants exercisable at $1.64 per share. The offering includes a registered direct offering and a concurrent private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
-
News

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reports a 375% growth in CyPath® Lung tests ordered and processed over the past three months. The company attributes this growth to the introduction of a reimbursement code, completion of branding, and expansion of the sales force. The successful integration of the commercial laboratory has also contributed to the increasing physician interest and adoption of the noninvasive test for early-stage lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.66%
Tags
none
-
News

bioAffinity Technologies News Update

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF) announces significant developments, including the addition of CyPath® Lung test to Lung Innovations Network, expansion of sales team, addition of Dr. Sandeep Bansal to advisory board, and participation in American Thoracic Society's conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
News

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has announced the addition of Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, to the company's team. The company is focused on noninvasive tests for early-stage cancer detection, including CyPath® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
management
-
News

bioAffinity Technologies In The News

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has recently achieved CAP accreditation for its Precision Pathology Laboratory Services, received a patent in India for targeted cancer treatment, and has been collaborating with ScienceSoft. The company's subsidiary, OncoSelect Therapeutics, LLC, has expanded its intellectual property portfolio to 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Rhea-AI Summary
bioAffinity Technologies, Inc. has been granted a patent in India for porphyrin compounds used in targeted cancer treatment. This patent adds to the company's existing patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications. The company's first product, CyPath® Lung, is a noninvasive diagnostic test for early-stage lung cancer, utilizing advanced flow cytometry and artificial intelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
News

bioAffinity Technologies In the News

Rhea-AI Summary
SAN ANTONIO announces partnership with XYZ Pharmaceuticals to develop new cancer treatment - Ticker Symbol: SA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
News

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rhea-AI Summary
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (BIAF) and BioVie, Inc. (BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. BioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment, with a focus on lung cancer detection. The company's flagship product, CyPath® Lung, has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The company also holds extensive U.S. and international patents and has strong insider ownership at 39%. BioVie, Inc. is a clinical-stage company developing therapies for Alzheimer's, Parkinson's, refractory ascites, and HRS-AKI. The company recently reported positive trending data from a Phase 3 trial in Alzheimer's and has plans to launch Phase 3 trials in 2024 for Alzheimer's, Parkinson's, and Ascites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
none
-
News

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the appointment of Jamie Platt, Ph.D., to its Board of Directors, effective Dec. 1, 2023. Dr. Platt brings two decades of experience in diagnostic technologies and has been instrumental in two M&A exits for diagnostic companies in 2022, resulting in a combined value of nearly $1 billion. She has extensive experience in expanding product market share in the diagnostics market. Dr. Platt's appointment is expected to drive bioAffinity's growth and success, particularly in commercializing CyPath® Lung, their noninvasive test for the early detection of lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
management
News

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. The CMS payment determination is a major milestone that facilitates reimbursement by both Medicare and private payers, making the test more attractive to physicians and their patients at high risk for lung cancer. The test showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients with small lung nodules less than 20 millimeters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
none

FAQ

What is the current stock price of bioAffinity Technologies (BIAF)?

The current stock price of bioAffinity Technologies (BIAF) is $0.9928 as of December 20, 2024.

What is the market cap of bioAffinity Technologies (BIAF)?

The market cap of bioAffinity Technologies (BIAF) is approximately 19.9M.

What does bioAffinity Technologies, Inc. specialize in?

bioAffinity Technologies specializes in developing noninvasive diagnostic tests and targeted cancer treatments at the cellular level.

What is CyPath® Lung?

CyPath® Lung is a noninvasive test developed by bioAffinity Technologies for the early detection of lung cancer using flow cytometry technology.

Who has licensed CyPath® Lung for development?

CyPath® Lung has been licensed by Precision Pathology Services for further development and commercial sale.

What recent financial agreement has bioAffinity Technologies entered into?

The company has entered into a securities purchase agreement with institutional investors, involving a registered direct offering and a concurrent private placement.

What is the anticipated financial benefit of the recent securities offering?

The offering is expected to raise approximately $2.5 million, excluding potential proceeds from warrant exercises.

Who is assisting bioAffinity Technologies with their financial transactions?

WallachBeth Capital LLC is acting as the sole placement agent for the company's financial transactions.

What are the future plans for bioAffinity Technologies?

bioAffinity Technologies plans to continue the development and commercialization of their diagnostic tests and cancer therapeutics, leveraging the proceeds from recent financial transactions.

How does CyPath® Lung improve patient outcomes?

CyPath® Lung improves patient outcomes by increasing diagnostic accuracy, reducing the need for invasive procedures, and lowering medical costs.

Where can I find more information about the registered direct offering?

Details about the registered direct offering can be found in the prospectus supplement filed with the SEC, available on their website.

What technology does bioAffinity Technologies focus on for their products?

The company focuses on technology that targets cancer cells and cell populations indicative of disease, primarily using flow cytometry in their diagnostics.

Stock BIAF logo
bioAffinity Technologies, Inc.

Nasdaq:BIAF

BIAF Rankings

#5314 Ranked by Market Cap
N/A Ranked by Dividends

BIAF Stock Data

19.88M
11.08M
29.55%
3.03%
1.75%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
SAN ANTONIO